Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Poniatowa – page 21

827 clinical trials in Poniatowa, Poland across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Poniatowa at a glance
827
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

827 trials in Poniatowa

Open in trial search

Chronic lymphocytic leukaemia

Recruiting

Study Comparing Pirtobrutinib and Ibrutinib for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Loxo Oncology Inc.

Acute myeloid leukaemia

Recruiting

Study on Personalized Treatment for Acute Myeloid Leukemia Using Cladribine, Daunorubicin, Cytarabine, and Drug Combinations for Specific Patient Groups

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cladribine
  • Sponsor:Medical University Of Lodz

Colitis ulcerative

Recruiting

Study Comparing Vedolizumab and Infliximab for Children Aged 6-17 with Ulcerative Colitis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Infliximab
  • Sponsor:Instytut Pomnik Centrum Zdrowia Dziecka

Relapsing multiple sclerosis+2

Recruiting

Study on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Teriflunomide
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Myelofibrosis

Recruiting

Study for Myelofibrosis Patients Using Ruxolitinib or Ruxolitinib with Other Cancer Treatments

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Seizure

Recruiting

Study on the Safety of Alprazolam for Treating Long Seizures in Patients Aged 12 and Older

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alprazolam
  • Sponsor:UCB Biopharma

Non-small cell lung cancer

Recruiting

Study of MK-1084 and Pembrolizumab for First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation and High PD-L1 Levels

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:MK-1084
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma

Recruiting

Comparison of belantamab mafodotin, bortezomib and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Glaxosmithkline Research & Development Limited

Myelofibrosis+1

Recruiting

Study on the Effectiveness and Safety of Selinexor for Patients with Myelofibrosis and Moderate Thrombocytopenia Who Have Not Used JAK Inhibitors

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:Karyopharm Therapeutics Inc.

Bladder transitional cell carcinoma

Recruiting

Study Comparing Erdafitinib and Mitomycin for Patients with Intermediate-risk Non-muscle Invasive Bladder Cancer with FGFR Gene Alterations

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Erdafitinib
  • Sponsor:Janssen Cilag International

Chronic lymphocytic leukaemia+1

Recruiting

Study Comparing Nemtabrutinib, Ibrutinib, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Merck Sharp & Dohme LLC

Psoriasis

Recruiting

Study on Tildrakizumab and Etanercept for Children Aged 6 to 17 with Moderate to Severe Plaque Psoriasis

Registered drug
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Etanercept
  • Sponsor:Sun Pharmaceutical Industries Limited

Other cities in Poland

The busiest research cities in the country

All 236 cities in Poland

Clinical research in Poniatowa

What the registry says about research in the country

01 Cardiovascular Research

Innovative clinical trials focusing on hyperlipidemia management, specifically targeting patients at high and very high cardiovascular risk. The research evaluates the effectiveness of rosuvastatin treatments and combination therapies in achieving optimal LDL-C reduction.

  • Lipid Management
  • Cardiovascular Risk Prevention
  • Combination Therapy Assessment

These studies aim to establish more effective treatment protocols for patients requiring intensive lipid-lowering therapy.

02 Rheumatology Studies

Comprehensive research evaluating biosimilar treatments for rheumatoid arthritis. The trials compare the efficacy of new biosimilar options with established treatments, focusing on patients with moderate to severe disease conditions.

  • Biosimilar Development
  • Treatment Efficacy Assessment
  • Immunogenicity Studies

This research aims to expand treatment options while maintaining high efficacy standards in rheumatoid arthritis management.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.